Fulltext

Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer

Oldenburg, J. ; Aparicio, J. ; Beyer, J. ; Cohn-Cedermark, G. ; Cullen, M. ; Gilligan, T. ; De Giorgi, U. ; De Santis, M. ; de Wit, R. ; Fosså, S. D. ; Germà-Lluch, J. R. ; Gillessen, S. ; Haugnes, H. S. ; Honecker, F. ; Horwich, A. ; Lorch, A. ; Ondruš, D. ; Rosti, G. ; Stephenson, A. J. ; Tandstad, T.

In: Annals of Oncology, 2015, vol. 26, no. 5, p. 833-838

Ajouter à la liste personnelle
    Titre
    • Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
    Auteur
    • Oldenburg, J.. Department of Oncology, Akershus University Hospital, Lørenskog
    • Aparicio, J.. Department of Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
    • Beyer, J.. Department of Oncology, Universitätsspital Zürich, Zürich, Switzerland
    • Cohn-Cedermark, G.. Department of Oncology-Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
    • Cullen, M.. Department of Medical Oncology, Queen Elizabeth Hospital, University Hospital Birmingham Foundation Trust, Birmingham, UK
    • Gilligan, T.. Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, USA
    • De Giorgi, U.. Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
    • De Santis, M.. Kaiser Franz Josef Hospital and ACR-ITR and LBI-ACR Vienna-CTO, Vienna, Austria
    • de Wit, R.. Erasmus University Medical Center, Rotterdam, The Netherlands
    • Fosså, S. D.. Department of Oncology, Oslo University Hospital, University of Oslo, Oslo, Norway
    • Germà-Lluch, J. R.. Department of Oncology, Institut Català d'Oncologia, Gran Via de l'Hospitalet Hospitalet de Llobregat, Barcelona, Spain
    • Gillessen, S.. Department of Medical Oncology, Kantonsspital, St Gallen, Switzerland
    • Haugnes, H. S.. Oncology Department, University Hospital of North Norway, Tromsø, Norway
    • Honecker, F.. Tumor and Breast Center ZeTuP, St. Gallen, Switzerland
    • Horwich, A.. Department of Clinical Oncology, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK
    • Lorch, A.. Klinik für Urologie, konservative Uroonkologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
    • Ondruš, D.. Department of Oncology, Comenius University Faculty of Medicine, St Elisabeth Cancer Institute, Bratislava, Slovak Republic
    • Rosti, G.. Medical Oncology, Ospedale Generale, Treviso, Italy
    • Stephenson, A. J.. Department of Urology, Cleveland Clinic, Cleveland, USA
    • Tandstad, T.. The Cancer Clinic, St Olavs University Hospital, Trondheim, Norway
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2015, vol. 26, no. 5, p. 833-838. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:290634
    Summary
    Testicular cancer (TC) is the most common neoplasm in males aged 15 to 40 years and approximately 65%-75% have clinical stage I (CSI) disease. Both surveillance and adjuvant chemotherapy may be applied with indistinguishable long-term survival rates. Therefore, the patient should decide based on risk factors and potential benefits and harms rather than adopting a uniform recommendation for all